| 27.06 17:00 | dpa-AFX: AbbVie Acquires Celsius Therapeutics For $250 Mln |
| 27.06 15:31 | dpa-AFX: *ABBVIE ACQUIRES CELSIUS THERAPEUTICS FOR $250 MLN IN CASH |
| 27.06 14:32 | dpa-AFX: *ALLERGAN AESTHETICS LAUNCHES ALLE PAYMENT PLANS POWERED BY CHERRY |
| 27.06 02:52 | dpa-AFX: Genmab's EPKINLY Receives FDA Accelerated Approval For R/R Follicular Lymphoma |
| 25.06 14:28 | dpa-AFX: AbbVie: FDA Issues CRL For ABBV-951 |
| 25.06 14:17 | dpa-AFX: *ABBVIE RECEIVES FDA COMPLETE RESPONSE LETTER FOR ABBV-951 IN PARKINSON'S DISEASE TREATMENT |
| 21.06 14:03 | dpa-AFX: *ABBVIE (ABBV) DECLARES QUARTERLY DIVIDEND OF $ 1.55, RECORD DATE 7/15/2024 |
| 21.06 14:02 | dpa-AFX: *ABBVIE DECLARES QUARTERLY CASH DIVIDEND OF $1.55/SHR; PAYABLE AUGUST 15/RECORD JULY 15 |
| 20.06 14:02 | dpa-AFX: *ABBVIE APPOINTS ROXANNE S. AUSTIN AS LEAD INDEPENDENT DIRECTOR, EFFECTIVE JULY 1 |
| 19.06 07:26 | dpa-AFX: AbbVie's Skyrizi Gets Approval In US For Ulcerative Colitis |
| 13.06 14:31 | dpa-AFX: AbbVie To Receive License From FutureGen To Develop, Commercialize FG-M701 |
| 13.06 14:02 | dpa-AFX: *ABBVIE AND FUTUREGEN STRIKE $1.71 BLN DEAL TO DEVELOP NEXT-GENERATION THERAPY FOR INFLAMMATORY BOWEL DISEASE |
| 13.06 14:00 | dpa-AFX: *ABBVIE, FUTUREGEN TO DEVELOP NEXT-GENERATION THERAPY FOR INFLAMMATORY BOWEL DISEASE |
| 12.06 15:02 | dpa-AFX: AbbVie To Present At Goldman Sachs Global Healthcare Conference; Webcast At 10:00 AM ET |
| 06.06 15:34 | dpa-AFX: AbbVie Reports Positive Results From Phase 2 PICCOLO Trial Of Mirvetuximab Soravtansine In PSOC |
| 06.06 14:47 | dpa-AFX: *ABBVIE ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER |
| 05.06 15:02 | dpa-AFX: *ABBVIE SAYS FIRST PATIENT TREATED WITH INVESTIGATIONAL ABBV-383 IN CERVINO PHASE 3 STUDY |
| 05.06 06:32 | dpa-AFX: *HSBC HEBT ABBVIE AUF 'BUY' - ZIEL 185 USD |
| 05.06 06:32 | dpa-AFX: *HSBC RAISES ABBVIE TO 'BUY' - PRICE TARGET 185 USD |
| 04.06 15:00 | dpa-AFX: AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients |
|
|
